PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: R&D
Not Just Numbers: R&D Decline Measured in More Than NMEs
The hard (declining) numbers of approved NMEs in the past 10 to 15 years tell a powerful story. But is it the whole story?
It's Industry's Problem: A Fresh Take on R&D Costs
High in-house failure rates are slowing progress on pricing affordability, says GSK CEO Andrew Witty.
If there is one message that big pharma has applied consistently over the years, it is that drug development is very expensive. Big bucks and long-term investment in the institutional know-how and capacity built exclusively through private enterprise are what count [...]
Leniency and Flexibility: The Optimum Conditions for Innovation
Leniency and staff reward/recognition are key to improving R&D and product innovation, according to the first of three new Economist Intelligence Unit reports. Innovation Imperative in Biopharma focuses on the how to curb wasteful R&D spending and how to strengthen innovation abilities. The study is based on a survey of 282 senior executives, each of [...]
Posted in Global, Guest Blog, People, R&D, Strategy Also tagged Economist Intelligence Unit. innovation Leave a comment
Planning Beyond the Petri Dish: A Pfizer Case Study
Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk.
The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a [...]
Posted in Emerging Markets, Global, R&D Also tagged Asia, crizotinib, Emerging Markets, Japan, Korea, NSCLC, Pfizer Leave a comment
Calculating the Cost of R&D: Defending Tufts Research